THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population.
THOUSAND OAKS, Calif., Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024. The dividend will be paid on September 6, 2024, to all stockholders of record as of the close of business on August 16, 2024.
Comments: Repatha (evolocumab) sales increased 33% to $517 million in the quarter, driven by 44% volume growth. TEZSPIRE (tezepelumab-ekko) generated $173 million of sales in the quarter, up 80%, primarily driven by volume growth. Otezla (apremilast) sales were $394 million, an increase of 1%. Enbrel (etanercept) generated $567 million of sales, down 2%. AMJEVITA/AMGEVITA (adalimumab) generated $168 million of sales, up 2%. EVENITY (romosozumab-aqqg) sales increased 35% to $342 million, primarily driven by volume growth. BLINCYTO (blinatumomab) sales increased 26% to $244 million. TAVNEOS (avacopan) sales were $51 million, up 122% driven by volume growth. Prolia (denosumab) generated $999 million of sales, up 8% driven by volume growth Vectibix (panitumumab) sales were $247 million, up 6%. KYPROLIS (carfilzomib) sales increased 5% to $376 million. XGEVA (denosumab) sales increased 5% to $561 million. Nplate (romiplostim) generated $317 million of sales in the quarter, down 12%. MVASI (bevacizumab-awwb) sales were flat at $202 million.
Amgen Presents New Research On Otezla® (Apremilast) At Aad 2024
Mankind Pharma`s Generic Apremilast Receives Approval in the U.S.
Apopharma`s Generic Apremilast Receives Approval in the U.S.
NORTH CHICAGO, Ill., July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1 This study achieved all primary and ranked secondary endpoints with no new safety signals identified.1
Shilpa's Generic Apremilast Receives Approval in the U.S.
We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.